Eli Lilly invests $2.7 Billion in North Carolina Manufacturing Facility
Eli Lilly and Company will invest $2.7 billion too build a new manufacturing facility in research Triangle Park, North Carolina, considerably expanding its production capacity. Pennsylvania Governor Josh Shapiro announced the commitment after the site prevailed over more than 300 applicants.
key factors in the decision included proximity to leading technical universities, a robust local manufacturing industry, and existing infrastructure. The new facility will focus on manufacturing pharmaceutical products, though specific details about which drugs will be produced there have not yet been disclosed.
Part of a $50 Billion Expansion Strategy
Since 2020, Eli Lilly has announced investments totaling over $50 billion in ten U.S. manufacturing sites. Most recently, in December 2023, the company announced a $6 billion investment in huntsville, Alabama, for the production of pharmaceutical ingredients [Reuters]. These investments aim to bolster the company’s supply chain and meet growing demand for its products.
Eli Lilly is also progressing with the approval process for its oral weight-loss drug, Orforglipron. The FDA recently pushed back its decision date to April 10, 2026 [Fierce Pharma]. The delay is not uncommon and allows the agency more time to review the data submitted by the company.
Eli Lilly is scheduled to report its fourth-quarter 2023 earnings on February 1, 2024. [Eli Lilly Investor Relations] Investors will be closely watching to see how the company’s aggressive expansion plans are impacting its financial performance.The considerable investments are expected to yield returns in the coming years as the new facilities come online and begin producing revenue.
Key Takeaways
- Eli Lilly is investing $2.7 billion in a new North Carolina manufacturing facility.
- This is part of a larger $50 billion investment in U.S.manufacturing since 2020.
- The FDA has delayed its decision on Orforglipron to April 10, 2026.
- Investors will be scrutinizing Eli Lilly’s Q4 2023 earnings for signs of progress on its expansion strategy.